Get coverage of the latest pharmaceutical business developments

We’ll keep you up to date with the most recent business deals. Plus, you’ll have access to historical metrics on financing, licensing, partnership, and acquisition details to help you benchmark deals to structure future deals.

As a business and portfolio strategy professional, it’s important that you understand the diseases and market landscape, unmet needs, and the best candidates available for in-licensing, out-licensing or acquisition. To best evaluate your target list, you need to benchmark other relevant transactions in the space, and compare deal structures and mix of financial payments and milestones. You’ll want to:

Know when a candidate fitting your strategy moves into Phase II and in which diseases
Understand the current competition, and assess recent in- and out-licensing activity for similar drugs, or disease population

Alerts for these potential opportunities are a must-have.

How we can help

With our comprehensive coverage of industry meetings and financial conferences, and analyst calls, we arm you with timely and accurate intelligence you can act on, including:

Coverage of deals, partnerships, acquisitions, and venture financing
Benchmarking trends for drugs and deals
Drug pipeline tracking and assessment
Patent and generic coverage
Clinical and regulatory events
Likelihood of product approval and advisory committee insights
Drug delivery technologies
Competitive landscape tools and analysis
Company profiles

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Scrip

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

By Jung Won Shin 25 Oct 2022

AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.

Scrip

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 20 Oct 2022

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

Biomedtracker, Meddevicetracker

Q2 2022 Outlook Report

23 May 2022

In this report, we cover catalysts from 31 drugs, devices, diagnostics, and deals expected to occur in the second quarter of 2022.

Chemist + Druggist Data

New pip codes for Northern Ireland and Great Britain

11 Mar 2022

We are pleased to announce that from mid-February 2022, C+D Data will provide the UK supply chain with additional product listings and associated PIP-codes for Northern Ireland (NI) and Great Britain (GB.) This solution will allow you to reach the entire UK market quickly and facilitate the ordering and distribution of medicines without disruption to you, and your wholesalers – while ensuring the data’s accuracy, visibility, and long-term management.

Biomedtracker, Meddevicetracker

Don’t miss your free extract of Early 2022 Outlook Report

08 Feb 2022

In pharma’s fast paced and continually evolving world, accurately anticipating the impact of events on the horizon is critical to your success.

Scrip

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

By Scrip Team 18 Jan 2022

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.

Scrip

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

By Joseph Haas 17 Jan 2022

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 17 Jan 2022

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Scrip

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

By Scrip Team 17 Jan 2022

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

HBW Insight

US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

By Ryan Nelson 14 Jan 2022

Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

Scrip

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

By Alaric DeArment 10 Jan 2022

CancerCells_Creations_223873720_1200x675

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.